ibusinesslines.com
ibusinesslines.com November 22, 2017


Alder BioPharmaceuticals, Inc. (ALDR) Set to Announce Quarterly Earnings on Monday

17 July 2017, 09:17 | Kelvin Horton

Investors who are keeping close eye on Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) from a strong sell rating to a sell rating in a report issued on Tuesday, June 20th. The stock now has a consensus rating of "Buy" and an average price target of $35.00. Including today's unusual volume, Eiger BioPharmaceuticals, Inc.'s stock is performing at -20.60% on the year. It discovers, develops and seeks to commercialize therapeutic antibodies. Needham maintained the shares of ALDR in report on Thursday, June 8 with "Buy" rating. Aegis restated a "buy" rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 5th. Jefferies Group LLC restated a buy rating and set a $43.00 target price on shares of Alder BioPharmaceuticals in a report on Monday, April 17th. Finally, Oppenheimer Holdings, Inc. set a $34.00 target price on shares of Eiger BioPharmaceuticals and gave the stock a buy rating in a report on Saturday, April 8th. Alder Biopharmaceuticals had 19 analyst reports since August 6, 2015 according to SRatingsIntel. Also, there are 1 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.63 average brokerage recommendation. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of "Buy" and a consensus target price of $27.75. The company's stock had a trading volume of 91,683 shares. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $20.63. The stock has a 50-day moving average of $7.05 and a 200 day moving average of $9.94. This company shares are 208.07% off its target price of $35.89 and the current market capitalization stands at $584.83M. Over the last three months, the shares of the company have changed 8.82% and performed -21.28% over the last six months. On average, equities research analysts expect that Eiger BioPharmaceuticals will post ($5.39) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of worldwide copyright & trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/07/17/alder-biopharmaceuticals-inc-aldr-set-to-announce-quarterly-earnings-on-monday.html.


Several other institutional investors also recently made changes to their positions in ALDR. Fox Run Management L.L.C. purchased a new position in shares of Alder BioPharmaceuticals during the second quarter worth about $402,000. Zero analysts have provided estimates for Eiger BioPharmaceuticals' earnings, with the lowest EPS estimate coming in at ($1.51) and the highest estimate coming in at ($0.93). Bank of New York Mellon Corp boosted its position in shares of Eiger BioPharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company's stock worth $107,473,000 after buying an additional 230,044 shares during the period. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company's stock worth $157,000 after buying an additional 614 shares during the period. Finally, Vanguard Group Inc. raised its stake in Eiger BioPharmaceuticals by 1.6% in the first quarter. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.



Other News

Trending Now

Milan close to Morata — Gazzetta
Jose Mourinho admits Manchester United are unlikely to sign Real Madrid striker Alvaro Morata this summer. We worked with Gigio's willingness, and that of his family.

Swiss National Bank Has $1805000 Position in Dominion Diamond Corporation (DDC)
The basic materials company reported $0.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.04. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover DDC having a buy-equivalent rating.

Partly sunny, with highs in the upper 70s — Sunday weather
There's a severe thunderstorm warning for southeastern Jefferson County, southwestern Lewis County and northeastern Oswego County. Those who made a decision to start their weekend getaway at the shore early on Friday were in for a rude awakening.

Dupont Fabros Technology, Inc. (NYSE:DFT) Rating Lowered to Neutral at Macquarie
OppenheimerFunds Inc. boosted its position in shares of Dupont Fabros Technology by 159.4% in the first quarter. (NYSE:DFT). Stock rose 28.47% over the trailing 6 months. $85,726 worth of Mastercard Inc (NYSE:MA) was sold by Fraccaro Michael.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Downgraded by Morgan Stanley
According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $27.00 on company shares. Berson & Corrado Investment Advisors LLC increased its stake in Ocular Therapeutix by 5.8% in the first quarter.

Jay-Z Snags His 14th No. Album with '4:44'
The album, Jay-Z's first in four years, won favorable reviews and marked growing introspection from the 47-year-old rapper. Ever since Vol. 2.Hard Knock Life which came out in 1998, every one of Hov's solo efforts have reached the top spot.

West Brom sign Egypt defender Hegazi on loan
Hegazi, who stands at 6ft 5in, has not played in Europe since a three-year stint at Serie A side Fiorentina ended in 2015. Hopefully he'll be a good signing for us.